Market Insights

Before you chase a popular idea, check the stock holder page. It is the fastest way to see whether a trade is truly crowded or just widely known.

Lots of filers own the same mega-cap names. That does not mean they share the same thesis. Here is how to tell real consensus from shallow overlap.

The best watchlists combine institutional ownership with insider behavior. Here is a practical workflow using insider profiles, stock pages, and filer pages together.

Sometimes the headline 13F AUM and the visible holdings sum tell different stories. Here is how to sanity-check the numbers before you repeat the wrong one.

ETF-heavy filings can look active when they are really just broad exposure sleeves. Here is how to spot the difference before you copy the wrong signal.

Historical quarter pages are the easiest way to stop comparing the wrong snapshots. Here is how to use them to isolate real change instead of filing-noise.

A bigger 13F portfolio does not automatically mean a better idea source. Here is a cleaner way to compare managers using concentration, turnover, and stock-level context.

Simplex Trading reported a $177.41B Q4 2025 13F, but the filing reads less like a stock portfolio and more like an options-heavy market-structure book. That distinction is the whole story.

Q1 2026 13F filings are due May 15, 2026. Track Berkshire, Millennium, Bridgewater and more. See expected filing dates, AI/sector themes, and how to access data the moment it drops.

Buffett's Berkshire Hathaway holds $274B across 42 positions. Here's how to read his Q4 2025 13F — what he added, what he trimmed, and how to follow his next move before most investors notice.

Scotiabank's $131.31B investment arm entered 114 new positions in Q4 2025 while trimming its dominant internal fund by 25% — one of the most aggressive quarterly reshuffles among top-100 filers.

The 220-year-old London-based asset manager's US equity book reveals a distinctly European conviction — GOOGL as the #3 holding at 6.03%, plus aggressive adds in TEVA (+261%), CX (+406%), and new global commodity ETF positions.

CalPERS' latest 13F reveals $174.90B in reported AUM with VOO at 11.89% — nearly $20B in one S&P 500 ETF. Combined with NVDA at 8.55%, the top-2 holdings account for 20.44% of this pension giant's portfolio.

Israel Englander's multi-strategy giant allocated $34.15B to broad ETFs (IWM, IVV, QQQ, SPY) — the signature of pod-based beta hedging — while making outsized bets on WMT (+679% shares) and Bitcoin via IBIT.

Arrowstreet Capital's systematic models triggered one of Q4 2025's most aggressive Apple trims (-38% shares) while more than doubling Google. With 93 new positions and $170.74B in 13F assets, here's what the quant signals are saying.

Massachusetts Financial Services has seen AUM decline from $334B to $310B over 8 quarters — yet the 100-year-old fund is making its most aggressive portfolio rotation in years, slashing DXCM (-86%), TEAM (-80%), and VEEV (-78%) while piling into streaming and cloud.

UBS Asset Management's $472.97B portfolio reveals aggressive mega-cap tech concentration with NVDA at 8.13% weight, a $2.2B real estate exit from PLD and EQIX, and a staggering +1,064% increase in Netflix shares.

Janus Henderson (WhaleScore 75.50) opened 67 new positions while exiting 67 in Q4 2025 — a 13.4% turnover rate signaling active repositioning. New biotech/med-device bets (ISRG, GPCR, PTGX) hint at a healthcare conviction thesis.

Deutsche Bank AG's Q4 2025 13F reveals a systematic rebalancing at $307B AUM — cutting GOOGL (-14%), META (-11%), and AVGO (-10%) while loading Netflix shares by 968% and ServiceNow by 386%.

Two Protagonist Therapeutics insiders sold more than $8M of PTGX stock in late March as the biotech moved deeper into a milestone-rich phase with regulatory and trial catalysts ahead.